Evidence mapPaperPMID 42301351Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Exploring the material basis and potential mechanism of spleen-strengthening and damp-resolving prescriptions in the treatment of diabetes mellitus complicated with obesity based on data mining, UPLC-Q-TOF-MS/MS and network pharmacology.

Ruo Yang, Hongyang Li, Jinling Qiu, Meng Luo, Yifen Liu, Wei Gu

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruo Yang *Department of Pharmacy, Guangzhou University of Chinese Medicine Huizhou Hospital, Huizhou City, 516001, Guangdong Province, China.
Hongyang Li *Department of Pharmacy, Guangzhou University of Chinese Medicine Huizhou Hospital, Huizhou City, 516001, Guangdong Province, China.
Jinling Qiu *Department of Pharmacy, Guangzhou University of Chinese Medicine Huizhou Hospital, Huizhou City, 516001, Guangdong Province, China.
Meng LuoDepartment of Endocrinology, Guangzhou University of Chinese Medicine Huizhou Hospital, Huizhou, Huizhou City, 516001, Guangdong Province, China.
Yifen LiuDepartment of Endocrinology, Guangzhou University of Chinese Medicine Huizhou Hospital, Huizhou, Huizhou City, 516001, Guangdong Province, China.
Wei GuDepartment of Pharmacy, Guangzhou University of Chinese Medicine Huizhou Hospital, Huizhou City, 516001, Guangdong Province, China. gzzyydxhzyxb@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes combined with obesity is a global public health problem, with insulin resistance and chronic low-grade inflammation as key mechanisms. TCM regards spleen deficiency and phlegm-dampness as its core pathogenesis. This study constructs a research paradigm integrating clinical RCT data mining, UPLC-Q-TOF-MS/MS experimental component identification and network pharmacology-based prediction.This study predicted the multi-component, multi-target and multi-pathway mechanisms of core spleen-strengthening and damp-resolving prescriptions for this comorbidity. High-frequency herbs were screened via data mining from RCTs; chemical components were experimentally identified by UPLC-Q-TOF-MS/MS; intersecting targets and pathways were predicted by network pharmacology and preliminarily verified by semi-flexible molecular docking and molecular dynamics simulation. A 7-herb core prescription and 30 active components (nobiletin, puerarin, etc.) were determined. 350 common targets and hub genes (AKT1, MTOR, MMP9, PTGS2) were screened, with PI3K-Akt, lipid-atherosclerosis and diabetic AGE-RAGE as main pathways. Molecular docking showed strong component-target binding, which was further validated by dynamics simulation. The prescription improves diabetes with obesity through synergistic networks, regulating glycolipid metabolism and inflammation via the above pathways, supporting its modern clinical application.

Indexed as

Data miningDiabetes mellitusNetwork pharmacologyObesitySpleen-strengthening and damp-resolvingUPLC-Q-TOF–MS/MS

Identifiers

PMID42301351

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.